Evidence map›Paper›PMID 30255546›Full record

ArticlePediatric blood & cancer2019

Fetal programming and Wilms tumor.

Julia E Heck, Di He, Carla Janzen, Noah Federman, Jorn Olsen, Beate Ritz, Johnni Hansen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pediatric blood & cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Spina bifida and pediatric cancers.Pediatric hematology and oncology · 2020
    Article
  11. Phototherapy and childhood cancer: Shared risk factors.International journal of cancer · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Julia E HeckDepartment of Epidemiology, Fielding School of Public Health, University of California, Los Angeles, California.ORCID 0000-0001-8713-8413
Di HeDepartment of Epidemiology, Fielding School of Public Health, University of California, Los Angeles, California.
Carla JanzenDepartment of Obstetrics and Gynecology, Geffen School of Medicine, University of California, Los Angeles, California.
Noah FedermanDepartment of Pediatrics, Geffen School of Medicine, University of California, Los Angeles, California.
Jorn OlsenDepartment of Clinical Epidemiology, Aarhus University, Aarhus, Denmark.
Beate RitzDepartment of Epidemiology, Fielding School of Public Health, University of California, Los Angeles, California.
Johnni HansenDanish Cancer Society Research Center, Copenhagen, Denmark.

Funding

Maternal comorbidities, prescription drug use in pregnancy and childhood cancerR21CA175959 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HECK, JULIA · 2014 to 2015
$323k
Parental Occupation and Childhood CancersR03ES021643 · NIEHS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HECK, JULIA · 2012 to 2013
$152k
NCI NIH HHS R21 CA175959NIEHS NIH HHS R03 ES021643NIH HHS R03ES021643NIH HHS R21CA175959
6 · The paper itself

Abstract

backgroundThe "fetal programming" hypothesis has been evaluated in many adult diseases including cancer, but not for Wilms tumor. Wilms tumor has been related to high birthweight, but little is known about other growth metrics such as a baby's birth length, ponderal index, or placenta size, which can shed additional light on growth patterns.

methodsCases of Wilms tumor (N = 217) were taken from the Danish Cancer Registry, and controls (N = 4340) were randomly selected from the Population Register and matched to cases by sex and age. Linkage to the Medical Births Registry provided information on gestational factors and fetal growth measurements, while linkage to the Patient Register provided information on maternal and child health conditions.

resultsDespite having typically normal to higher birthweights, Wilms tumor cases had smaller placentas (≤540 g; odds ratio (OR) = 4.24; 95% confidence interval (CI), 1.84-9.78) and a lower placenta-to-birthweight ratio (OR = 1.81; 95% CI, 1.17-2.82, per 1 SD decrease). Small placentas were more common among Wilms cases without congenital anomalies (OR = 6.43; 95% CI, 1.95-21.21). Wilms tumor cases had a higher prevalence of high birthweight (>4000 g; OR = 1.57; 95% CI, 1.11-2.22), birth length 55 cm or longer (OR = 1.74; 95% CI, 1.09-2.78), and being large for gestational age (OR = 1.79; 95% CI, 1.08-2.96).

conclusionsOur study corroborates earlier studies showing associations with high birthweight and suggests associations between Wilms tumor and decreased placental size and low placenta-to-birthweight ratio.

Indexed as

Birth WeightFetal DevelopmentAdultCase-Control StudiesFemaleFollow-Up StudiesGestational AgeHumansInfant, NewbornKidney NeoplasmsMalePlacentaPregnancyPrognosisRegistriesWilms Tumorbirthweightbody sizefetal developmentnephroblastomaplacenta

Identifiers

PMID30255546
PMCPMC6530460

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.